Manifest Technologies is a Yale spinout formed in 2021, building on >$50M in NIH funding to the founders' laboratories. We are accelerating Central Nervous System (CNS) drug R&D through an automated and scalable computational neuroimaging platform that integrates human and animal neuro data to de-risk CNS drug R&D across phases through precision neural target selection. Our platform is a scalable & automated neuroimaging ML-driven system to inform neural drug target engagement, indication & patient stratification for CNS R&D. Manifest Technologies is developing solutions to: 1) Increase confidence in both established and novel target mechanisms, by mapping animal neuroimaging data to relevant human circuitry and thus enabling an early go/no-go decision. 2) Discover novel human neural targets for emerging or existing drugs by mapping neuroimaging effects to relevant symptoms/disorders in humans. 3) Enrich clinical trials with the patients most likely to respond to a drug by using established neurobehavioral assessments that are quantitatively optimized for the desired neural targets using our proprietary ML technology. We are doing this through our large-scale multimodal data lake powers our proprietary data-driven computational neuroimaging solutions.